Q2 Solutions & Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Tr...
June 08 2021 - 7:00AM
Business Wire
Q2 Solutions, a wholly-owned subsidiary of IQVIA and a leading
clinical trial laboratory services organization, today announced a
transformative collaboration with Tasso Inc., a pioneer in
clinical-grade, at-home, patient-centered blood testing, to develop
diagnostic tests used in decentralized (virtual) clinical trials.
These new laboratory-developed tests will use Tasso’s devices,
enabling patients to collect their own blood using a virtually
painless process from anywhere at any time.
“The current COVID-19 pandemic has created a surge in demand for
more virtual clinical trials and remote patient monitoring
applications,” said Ben Casavant, PhD, CEO and Co-founder of Tasso.
“Tasso is now poised to accelerate this paradigm shift in patient
care through our clinical-grade and convenient blood collection
experience. We are excited to partner with an industry leader like
Q2 Solutions to expand our growing menu of pre-validated assays and
enable more individuals to benefit from the latest advances in
clinical trials and diagnostic testing.”
Tasso’s devices enable patients to collect their own blood
samples for analysis without any training or the need to travel to
a physician’s office, hospital, or other clinical site – reducing
the burden of participating in a clinical trial. The devices are
currently in use by leading pharmaceutical companies across
multiple clinical trials for their research and development
efforts.
“We are delighted to collaborate with Tasso on this innovative,
patient-centric approach to blood collection for decentralized
clinical trials,” said Brian O’Dwyer, CEO of Q2 Solutions. “Prior
to formalizing the agreement, we completed a pilot study of
traditional methods of drawing blood using needle injections
directly into veins compared with capillary blood draws, which are
closer to the surface of the skin, and easier to complete using the
innovative Tasso devices. We were able to consistently capture
large capillary blood volumes that closely matched amounts from the
same participants versus standard methods.”
About Q2 Solutions
Q2 Solutions is a leading global clinical trial laboratory
services organization providing comprehensive testing, project
management, supply chain, biorepository, biospecimen and consent
tracking solutions. Leveraging our next generation technologies, we
deliver agile and precise services designed to meet the diverse
needs of our clients. We provide scientific expertise and
innovative solutions for ADME, bioanalytical, genomics, vaccines
and central laboratory services, including flow cytometry, anatomic
pathology, immunoassay, molecular and companion diagnostics, with
meticulous regional and global clinical trial implementation
support and high-quality data delivery. At Q2 Solutions, our work
is rooted in research, grounded in collaboration, and guided by our
passion to turn the hope of patients and caregivers around the
world into the help they need. To learn more, visit
www.q2labsolutions.com.
About Tasso
Tasso is an emerging healthcare company that is transforming the
traditional blood collection process with a more convenient and
virtually painless approach that focuses on the patient. The
company’s devices allow people to collect blood with the push of a
button from the comfort and privacy of their home, and then mail
the samples back to a qualified laboratory for analysis.
Headquartered in Seattle, Tasso is privately held and funded by
grants from the Defense Advanced Research Projects Agency, Defense
Threat Reduction Agency, and the National Institutes of Health, by
investments from Hambrecht Ducera Growth Ventures, Merck Global
Health Innovation Fund, Foresite Capital, Vertical Venture
Partners, Techstars, and Cedars Sinai, and by co-development deals
with various industry leaders. For more information, please visit
www.tassoinc.com and follow @tassoinc.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 72,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210608005164/en/
Nick Childs, IQVIA Investor Relations (Nchilds@us.imshealth.com)
+1.973.316.3828
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2024 to May 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From May 2023 to May 2024